Pfizer Inc. (TSX:PFE)
Canada · Delayed Price · Currency is CAD | Market Cap | 198.67B +5.8% |
| Revenue (ttm) | 87.83B +1.4% |
| Net Income | 10.39B -5.0% |
| EPS | 1.82 -5.1% |
| Shares Out | n/a |
| PE Ratio | 19.12 |
| Forward PE | 8.77 |
| Dividend | 0.78 (6.84%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 149,729 |
| Average Volume | 225,001 |
| Open | 11.54 |
| Previous Close | 11.55 |
| Day's Range | 11.33 - 11.58 |
| 52-Week Range | 10.18 - 12.92 |
| Beta | n/a |
| RSI | 32.28 |
| Earnings Date | May 5, 2026 |
About Pfizer
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial numbers in USD Financial StatementsNews
PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’
Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed that President Donald Trump is set to announce…
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
10 abstracts, including two oral presentations, reinforce Astellas' long-term commitment to advancing oncology care TOKYO, May 18, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and C...
Quest Diagnostics, Altria, and 12 More Stocks That Are Coming Back to Life After a Rough Patch
Almost half of S&P 500 stocks are down for the year, but a bunch show signs they are reviving. Our screen spotlights the most promising.
Pfizer price target raised to $26 from $25 at Wolfe Research
Wolfe Research analyst Alexandria Hammond raised the firm’s price target on Pfizer (PFE) to $26 from $25 and keeps an Underperform rating on the shares following what the firm calls…
Mixed options sentiment in Pfizer with shares up 0.48%
Mixed options sentiment in Pfizer (PFE), with shares up 12c, or 0.48%, near $26.00. Options volume running well above average with 182k contracts traded and puts leading calls for a…
Arvinas price target raised to $16 from $14 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps a Neutral rating on the shares. Arvinas and Pfizer (PFE) entered into…
Pfizer says EC grants marketing approval to expand indication for Hympavzi
Pfizer (PFE) announced that the European Commission has granted marketing authorization to expand the approved indication for Hympavzi to include patients 12 years of age and older weighing at least…
European Commission Approves Pfizer's HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization to expand the approved indication for HYMPAVZI® (marstacimab) t...
Pfizer (PFE) Delivered a Solid Q1. The Patent Cliff Keeps Me Bearish
Pfizer ($PFE) delivered a solid Q1, reinforcing that the pharmaceutical giant’s core business remains relatively resilient even as COVID-related revenue continues fading into the background. However, ...
H.C. Wainwright says Pfizer handing off Veppanu to Rigel ‘makes strategic sense’
After Rigel Pharmaceuticals (RIGL) announced it has entered into an exclusive global licensing agreement with Pfizer (PFE) and Arvinas (ARVN) for Veppanu for the treatment of ER+/HER2-, ESR1-mutated a...
Arvinas, Pfizer enter license pact with Rigel Pharmaceuticals for Veppanu
Arvinas (ARVN) and Pfizer (PFE) have entered into a license agreement with Rigel Pharmaceuticals (RIGL) for the exclusive global development, manufacturing, and commercialization rights for Veppanu. V...
Rigel Pharmaceuticals enters license agreement with Arvinas, Pfizer
Rigel Pharmaceuticals (RIGL) announced that it has entered into an exclusive, global license agreement with Arvinas (ARVN) and Pfizer (PFE), subject to regulatory clearance, to develop, manufacture an...
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently approved breast cancer drug, marking Rigel's fourth commercial product on the market.
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on ...
Mixed options sentiment in Pfizer with shares down 1.52%
Mixed options sentiment in Pfizer (PFE), with shares down 40c near $25.66. Options volume running well above average with 208k contracts traded and calls leading puts for a put/call ratio…
Mixed options sentiment in Pfizer with shares up 0.28%
Mixed options sentiment in Pfizer (PFE), with shares up 8c, or 0.28%, near $26.52. Options volume roughly in line with average with 101k contracts traded and calls leading puts for…
Pfizer sees high-single-digit annual revenue increases 2029-2033, WSJ reports
Pfizer (PFE) expects to return to consistent growth by 2029, targeting high-single-digit annual revenue increases through 2033, supported by a predictable post-patent portfolio transition and a pipeli...
Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC
Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a “very c...
Pfizer CEO on AI-designed molecule, and race to use new tech
Pfizer CEO Albert Bourla says that company has reviewed its first AI-designed molecule. He says the company wants to be at the forefront of using artificial intellegence
3 Dividend Stocks for May 2026
This month's trio included a dividend aristocrat.
Pfizer Earnings Call Transcript: Q1 2026
Q1 2026 results exceeded expectations with strong revenue and EPS growth, driven by robust performance in oncology, migraine, and vaccines. Legal settlements and pipeline progress support a high single-digit revenue CAGR post-2028, with disciplined capital allocation and cost management.
Pfizer Posts Better-Than-Expected Revenue, Profit
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending
Pfizer posted higher first-quarter revenue but lower profit that was weighed down partially by higher research and development spending.
Pfizer Stock Edges Higher as Earnings and Revenue Beat Estimates
The drugmaker has been leaning on recently acquired products to offset a looming patent cliff.
Why selling these 3 dividend stocks could be a mistake
Investors are uncomfortable seeing losses, especially in stocks they rely on for steady income. Enterprise Products Partners (NYSE: EPD), Pfizer (NYSE: PFE) and UPS (NYSE: UPS) all fit that uneasy pro...